Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis

@article{Zhang2017GemcitabineIC,
  title={Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis},
  author={Xiu-Wei Zhang and Yuehong Ma and Yang Sun and Yu Cao and Qin Li and Chong-an Xu},
  journal={Targeted Oncology},
  year={2017},
  volume={12},
  pages={309-321}
}
BackgroundIt remains controversial whether the addition of a second cytotoxic agent can further improve the therapeutic effect of gemcitabine monotherapy in advanced or metastatic pancreatic cancer (LA/MPC).ObjectiveThe objective of the present systematic review and meta-analysis was to investigate the efficacy and safety of gemcitabine-based doublet chemotherapy regimens compared to single-agent gemcitabine in the first-line treatment of unresectable LA/MPC.MethodsWe searched for randomized… 

Combination therapy versus gemcitabine monotherapy in the treatment of elderly pancreatic cancer: a meta-analysis of randomized controlled trials

TLDR
Combined chemotherapy, but not for gemcitabine plus targeted agents, could be recommended for elderly PC patients due to its survival benefits and further studies are still needed to assess the treatment tolerance of combination chemotherapy in these patient populations.

Efficacy and safety of gemcitabine-capecitabine combination therapy for pancreatic cancer

TLDR
GemCap was associated with better outcomes of OS, PFS, PRR, ORR, as compared with Gem, which is likely to become a promising therapy for pancreatic cancer.

Survival benefits and safety of chemotherapy regimens for pancreatic cancer: An umbrella review of meta-analyses of randomized controlled trials

TLDR
It was shown that the use of combination chemotherapy regimens demonstrated survival benefits over gemcitabine monotherapy, which were supported by moderate to high-quality evidence.

Phase I/II Study of LDE225 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer

TLDR
LDE225 in combination with gemcitabine and nab-paclitaxel was well-tolerated in patients with metastatic PDAC and has promising efficacy after prior treatment with FOLFIRINOX and future phase III clinical trials should confirm these results.

Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review

TLDR
The molecular causes of gemcitabine resistance in PDAC are analyzed and the possibilities of new approaches aimed at decreasing, delaying or even reversing chemoresistance in pancreatic cancer are discussed.

Cancer Chemotherapy: The Case for Therapeutic Drug Monitoring.

TLDR
The challenges of dosing cytotoxic chemotherapies, dose determination strategies for cytot toxic, targeted, and antibody-based biological anticancer drugs, and an overview of the recent literature regarding the use of TDM in cancer are discussed.

Effect of metformin on the survival of patients with ALL who express high levels of the ABCB1 drug resistance gene

TLDR
The combined use of metformin with chemotherapy is effective in patients with elevated levels of ABCB1 gene expression, and there is a benefit to adding met formin in the group of patients with high ABCB 1 gene expression.

Combination therapy for the treatment of pancreatic cancer through hyaluronic acid‐decorated nanoparticles loaded with quercetin and gemcitabine: A preliminary in vitro study

TLDR
The produced HA‐decorated NPs loaded with GMC and QCT showed an improved cytotoxicity and cellular uptake toward two cell lines of pancreatic ductal adenocarcinoma, namely Mia‐PaCa‐2 and PANC‐1, compared with both the bare drugs and the drugs loaded in NPs which do not expose HA on the surface.

References

SHOWING 1-10 OF 76 REFERENCES

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

TLDR
Based on a preliminary subgroup analysis, pancreatic cancer patients with a good PS appear to benefit from GEM-based cytotoxic combinations, whereas patients with an initially poor PS seem to have no survival benefit from combination chemotherapy.

Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?

TLDR
Gem citabine combination therapy provides a modest improvement of survival, but is associated with more toxicity compared with gemcitabine monotherapy.

Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.

TLDR
Results of this trial suggest a fairly good therapeutic index for the combination of biweekly high-dose gem citabine and capecitabine for the treatment of advanced pancreatic cancer.

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.

TLDR
Results support the efficacy and safety of an every-2-weeks treatment with gemcitabine plus cisplatin as first-line chemotherapy for locally advanced or metastatic pancreatic cancer.

Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.

  • G. ColucciR. Labianca F. Perrone
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
TLDR
The addition of weekly cisplatin to gemcitabine failed to demonstrate any improvement as first-line treatment of advanced pancreatic cancer and combined therapy produced more hematologic toxicity, without relevant differences in nonhematologic toxicity.

Meta-analysis of inoperable pancreatic cancer: gemcitabine combined with cisplatin versus gemcitabine alone.

TLDR
GEM-DDP combination should not be recommended and GEM monotherapy remains the standard treatment for patients with APCa through meta-analysis.

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

TLDR
5-FU, administered in conjunction with gemcitabine, did not improve the median survival of patients with advanced pancreatic carcinoma compared with single-agent gemcitABine, and clinical trial resources should address other combinations and novel agents.

Combination chemotherapy in advanced pancreatic cancer: time to raise the white flag?

  • S. WelchM. Moore
  • Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
TLDR
The trial by Herrmann et al 6 is of high quality and was based on evidence from earlier phase studies that suggested the combination had sufficient activity to warrant further testing.

A randomized phase II study of gemcitabine plus S-1 versus gemcitabine alone in patients with unresectable pancreatic cancer.

  • Y. OmuroT. Ikari T. Nakajima
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
TLDR
The study showed the possibility that GS could be a first line therapy for unresectable pancreatic cancer, and a larger randomized phase III study is warranted.
...